Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Zura Bio LimitedNASDAQ: ZURA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $10.75M rose 22.5% year over year, ahead of the +1.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 44.2% from the prior quarter. Over 3 fiscal years it compounded at +112.2% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +7.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $10.75M+44.2% QoQ
- Last fiscal yearDec 2025
- $33.16M+7.7% YoY
- LTMMar 2026
- $35.14M+1.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +22.5% | -100.0% | -122.5 pp |
| 1 year | +7.7% | -100.0% | -107.7 pp |
| 3-year CAGR | +112.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 33.16M USD
- Year-over-year change
- +7.7%
- 4-year CAGR
- +134.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.16M | +7.7% |
| FY2024 | 2024-12-31 | 30.79M | +65.2% |
| FY2023 | 2023-12-31 | 18.64M | +436.7% |
| FY2022 | 2022-12-31 | 3.47M | +218.0% |
| FY2021 | 2021-12-31 | 1.09M | — |
Selling, General & Admin vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's LTM Mar 2026 selling, general & admin of $35.14M is the 4th highest of the 11 companies compared; the peer median is $23.7M.
- Its year-over-year change of +1.0% is the 6th highest of 11, against a peer median of -0.4%.
- Over three fiscal years its annual growth of +112.2% compares with a peer median of +1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.7B | +29505.3% | +3.5% | — | |
| LTM Mar 2026 | $43.57M | -11.6% | +0.0% | 96.1% | |
| LTM Mar 2026 | $38.28M | -25.4% | -1.1% | 55.3% | |
ZURAZura Bio Limited | LTM Mar 2026 | $35.14M | +1.0% | +112.2% | — |
| LTM Mar 2026 | $26.89M | -3.6% | -3.6% | 95.3% | |
| LTM Mar 2026 | $23.71M | -4.5% | +3.4% | 10537.3% | |
| LTM Mar 2026 | $23.69M | +2.7% | +2.7% | — | |
| LTM Mar 2026 | $20.02M | -13.1% | -15.9% | 144.4% | |
| LTM Mar 2026 | $19.78M | +10.8% | -6.4% | 27.8% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $18.03M | +5.9% | +42.7% | — |
| LTM Mar 2026 | $16.97M | +137.1% | +72.2% | — | |
| Peer median (excluding ZURA) | $23.7M | -0.4% | +1.4% | 95.7% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 23.69M | 44M | 24.4M | 42.08M |
| Selling, General & Admin | 1.09M | 3.47M | 18.64M | 30.79M | 33.16M |
| Operating Expenses | 1.09M | 27.16M | 62.64M | 55.19M | 75.25M |
| Depreciation & Amortization | 0 | 0 | 0 | 9K | 49K |
| EBITDA | 8.42M | (27.33M) | (60.56M) | (52.39M) | (68.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.09M) | (27.16M) | (62.64M) | (55.19M) | (75.25M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 23.48K | 570 | 2.19M | 8M | 6.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 9.51M | (171K) | 2.08M | 2.79M | 6.6M |
| Income Before Tax | 8.42M | (27.33M) | (60.56M) | (52.4M) | (68.65M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 8.42M | (25.74M) | (60.36M) | (52.4M) | (68.65M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | 0.40 | 0.21 | (2.09) | (0.60) | (1.06) |
| EPS (Diluted) | 0.40 | 0.21 | (2.09) | (0.60) | (1.06) |
| Weighted Avg Shares | 17.25M | 17.25M | 33.06M | 75.07M | 94.16M |
| Weighted Avg Shares (Diluted) | 17.25M | 17.25M | 33.06M | 75.07M | 94.16M |
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.